Vaccination programme shouldn`t be messy like relief packages thedailynewnation.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thedailynewnation.com Daily Mail and Mail on Sunday newspapers.
US health authorities launch study of rare allergic reactions to coronavirus vaccine Updated: December 21, 2020 Published December 21, 2020
Share on Facebook
Print article WASHINGTON - Officials at the National Institutes of Health are rushing to devise a study to find out why, in a few rare cases, people have had severe allergic reactions to the Pfizer coronavirus vaccine. The goal is to identify the component of the vaccine most likely to be responsible for these potentially life-threatening incidents, known as anaphylaxis. No cases have yet been associated with the other newly authorized vaccine, made by Moderna, but it is being administered to the general public for the first time this week and has similar components to the one developed by Pfizer and its partner BioNTech.
Juneau, Alaska (KINY) - Alaska received 26,800 doses of Moderna vaccine today.
The Alaska Department of Health reported five adverse reactions to the Pfizer vaccine. Two were reported at Bartlett Regional Hospital, one at Fairbanks Memorial, and two at Providence Alaska Medical Center in Anchorage.
Two of the five cases were considered anaphylaxis reactions.
5,674 vaccines have been administered so far in Alaska.
There have been over 272,000 doses of Pfizer vaccine administered in the United States with six cases of anaphylaxis.
The state did not have available the number of doses of Moderna vaccine being sent to each Alaska community.
Share
250 shanties gutted in fire at city`s Kalshi slum thedailynewnation.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thedailynewnation.com Daily Mail and Mail on Sunday newspapers.
The study will recruit volunteers who have had a history of severe allergic reactions and who will receive the vaccine under close clinical supervision, according to Daniel Rotrosen, director of the Division of Allergy, Immunology and Transplantation at the National Institute of Allergy and Infectious Diseases. This is not a simple study design, Rotrosen told
The Washington Post. We expect to be looking at highly allergic individuals. They will be not necessarily so easy to recruit, either. A lot still needs to be done to be sure we have the optimal study design. That said, we re trying to move as quickly as we can, for obvious reasons.